ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
7 announcements with these filters
Akums Drugs and Pharmaceuticals received an ESG rating of 65 for FY2025-26 from NSE Sustainability Ratings & Analytics Limited. The rating was assigned voluntarily based on publicly available information.
Akums Drugs and Pharmaceuticals Limited has cancelled its participation in the Antique Healthcare Investor Conference scheduled for August 25, 2026, due to unavoidable medical reasons.
Akums reported strong Q1FY27 performance with 13.9% revenue growth and 56.1% PAT increase. Results were driven by a robust 18.6% growth in the CDMO segment and improved API pricing.
The company filed its quarterly shareholding pattern for the period ended September 30, 2025, in compliance with SEBI LODR regulations.
Akums reported strong Q1 FY27 results with 13.9% revenue growth and 56.1% PAT growth. Strategy focuses on CDMO volume growth and expanding skincare/wellness via the Oriflame India manufacturing acquisition.
Akums Drugs reported Q1 FY27 consolidated revenue of ₹1,167 crore, reflecting 13.9% year-on-year growth. PAT rose to ₹101 crore compared to ₹65 crore in Q1 FY26.
Akums Drugs & Pharmaceuticals Ltd reported revenue from operations of ₹1,167 Cr (+13.9% YoY) and net profit of ₹101 Cr (+56.1% YoY) for Q1 FY27.